Diabetes & Obesity Breakthrough: Eli Lilly’s retatrutide trial reports obese adults with type 2 diabetes shedding up to about a quarter of body weight over 80 weeks while keeping blood sugar controlled, adding to the fast-moving race for next-gen metabolic drugs. Weight-loss Alternatives in Focus: Zealand Pharma says its amylin-based petrelintide Phase 2 data (published in The Lancet Diabetes & Endocrinology) show clinically meaningful double-digit weight loss and cardiometabolic improvements, positioning it as a potential option for people who struggle with GLP-1 side effects. Diabetes Tech Access: Dexcom’s EASD-linked report finds many type 2 diabetes clinicians see continuous glucose monitoring as essential, but reimbursement and coverage barriers still limit real-world impact. Healthcare Cybersecurity: A new report flags a second cyberattack targeting Polish medical software, raising fresh concerns about patient data protection. Road Safety (Poland): TV coverage in Kościerzyna shows a fatal crash scene where a second collision occurred—an electric scooter rider was hit by a car turning into a side street—prompting renewed attention on traffic safety around vulnerable road users. EU Health Policy Spillover: The EU Court of Justice rejected Poland’s bid to suspend the EU–Mercosur trade deal, a decision that could keep agricultural and food-safety debates in the spotlight. Regional Health Funding: V4 regional development talks (including Poland) put EU cohesion funding and the “Right to Stay” agenda—jobs, housing, transport, education and healthcare—on the table.